FY2024 EPS Estimates for Tenaya Therapeutics, Inc. Cut by Chardan Capital (NASDAQ:TNYA)

Tenaya Therapeutics, Inc. (NASDAQ:TNYAFree Report) – Chardan Capital decreased their FY2024 earnings per share estimates for Tenaya Therapeutics in a report released on Tuesday, May 28th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings of ($1.61) per share for the year, down from their previous estimate of ($1.10). Chardan Capital currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.54) per share.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Wednesday, May 15th. Canaccord Genuity Group dropped their price target on shares of Tenaya Therapeutics from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, May 16th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $15.00.

Read Our Latest Report on Tenaya Therapeutics

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock opened at $4.21 on Friday. The firm has a 50 day moving average price of $4.51 and a 200 day moving average price of $4.06. Tenaya Therapeutics has a fifty-two week low of $1.66 and a fifty-two week high of $8.09. The company has a market capitalization of $330.56 million, a PE ratio of -2.57 and a beta of 2.61.

Tenaya Therapeutics (NASDAQ:TNYAGet Free Report) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.05.

Institutional Trading of Tenaya Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. lifted its stake in shares of Tenaya Therapeutics by 4.5% in the 1st quarter. RA Capital Management L.P. now owns 5,755,050 shares of the company’s stock worth $30,099,000 after acquiring an additional 247,703 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Tenaya Therapeutics by 90.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 168,565 shares of the company’s stock worth $882,000 after purchasing an additional 80,212 shares in the last quarter. Vanguard Group Inc. increased its position in Tenaya Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock worth $14,973,000 after buying an additional 403,472 shares in the last quarter. HighPoint Advisor Group LLC purchased a new stake in Tenaya Therapeutics during the 4th quarter worth about $228,000. Finally, NEOS Investment Management LLC acquired a new position in shares of Tenaya Therapeutics in the fourth quarter valued at approximately $201,000. 90.54% of the stock is owned by institutional investors and hedge funds.

About Tenaya Therapeutics

(Get Free Report)

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.

Further Reading

Earnings History and Estimates for Tenaya Therapeutics (NASDAQ:TNYA)

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.